A-Z Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z ALL
Instagram Facebook Twitter Youtube
Reporting LAHAN Alerts

Coronavirus Disease 2019

Healthcare Provider
Information Hub


Please refresh your browser to see the latest updates and versions of our documents.
New and Noteworthy
For the latest information, view LA County data and DPH press releases. Join the Los Angeles Health Alert Network (LAHAN) to receive DPH email advisories on COVID-19 for health professionals.

Looking for New and Noteworthy COVID-19 vaccine updates? Visit the LAC DPH Vaccine Info Hub.


  • Evusheld is not currently authorized for use until further notice (1-26-23) The FDA has revised the Emergency Use Authorization for Evusheld (tixagevimab/cilgavimab) to limit its use to when the combined frequency of non-susceptible SARS-CoV-2 variants nationally is less than or equal to 90%. Per the most recent CDC Nowcast data, non-susceptible SARS-CoV-2 variants are projected to be more than 90% of current infections nationally. Evusheld, a combination of two long-acting anti-SARS-CoV-2 monoclonal antibodies , was the only medication authorized for pre-exposure prophylaxis (PrEP). See FDA announcement
  • CDC Webinar: Updates to COVID-19 Testing and Treatment for the Current SARS-CoV-2 Variants-Recorded on 1-24-23. View archived recording | See slides
  • CA Provider Therapeutics Warmline support now available. Beginning 1-9-23, health care providers can call 1-866-268-4322 (866-COVID-CA) to receive free and confidential consultation on COVID-19 testing and treatment. The COVID-19 Therapeutics Warmline is a real-time resource available to all California health care providers and is managed by the University of California, San Francisco (UCSF) National Clinician Consultation Center.
  • Updated NIH COVID-19 Treatment Guidelines Panel’s statement on Evusheld (1-10-23) Evusheld is unlikely to be effective at preventing COVID-19 in the vast majority of individuals due to the high prevalence of resistant Omicron subvariants. However, per the NIH Panel, because no alternative options for PrEP are available, clinicians can still administer Evusheld after considering an individual patient’s risks and the regional prevalence of the resistant subvariants. See NIH COVID-19 Treatment Guidelines Panel’s Statement on Evusheld
  • FDA Update on Evusheld (1-6-23) There may be an increased risk for developing COVID-19 when exposed to variants of SARS-CoV-2 that are not neutralized by Evusheld such as the BA 4.6 and XBB.1.5 variants. Individuals who received Evusheld and develop symptoms should be tested for COVID and treated if positive. FDA news release | Provider fact sheet.
  • CDC Important Updates on COVID-19 Therapeutics for Treatment and Prevention (12-21-22) The CDC issued a HAN to provide guidance on improving the use of therapeutics for the treatment of COVID-19 and strategies to prevent serious outcomes of COVID-19. Read LAHAN | Visit DPH COVID-19 Therapy for Non-Hospitalized Patients website.
Contact Us

DPH COVID-19 Provider Call-Line:

  • Healthcare provider questions on testing, reporting, or other COVID-related issues.
  • Clinical questions about the COVID vaccine including but not limited to contraindications, precautions, side effects, post-vaccination assessment.
  • For COVID-19 related discharge and transfer resources visit this webpage
  • Monday through Friday, 8:00am-5:00pm, call 213-240-7941. For time-sensitive questions after hours, call 213-974-1234 and ask for the on-call clinician

COVID-19 Vaccine Administration and Clinic Call-lines and Consultation see “Vaccine Contact Us

Medical professionals interested in supporting the COVID-19 response:

The CDC Clinician Call Center is available to clinicians who have COVID-19 clinical management questions. Call 800-CDC-INFO (800-232-4636) to be routed to Infectious Diseases Society of America (IDSA) volunteer clinicians.

LA County COVID-19 Data and Reports
  • LA County Daily COVID-19 Data webpage
  • NHSN COVID-19 Nursing Home Data for LA County: includes data reported to CDC’s National Healthcare Safety Network (NHSN) system COVID-19 Long Term Care Facility Module, including resident & staff case and death counts, county community rates, and an inventory of supplies & PPE. The data include PCR (but not antibody and antigen) test results. NHSN Data
  • Interactive COVID-19 surveillance dashboard: tables, maps, graphs, and charts including cases, counts by date, deaths, and tests performed. Dashboard
  • Healthcare Worker Cases: by occupational setting and role, known exposure and hospitalization and demographics of COVID-19-related healthcare worker deaths. HCW data
  • COVID Watch: a summary of COVID-19 surveillance and other virologic surveillance data for LA County. Includes local data on pneumonia, influenza, and COVID-19 mortality as well as ED visits for influenza-like illness. COVID Watch Webpage
Additional COVID-19 Resources

Icon: Get Adobe Reader
Adobe Reader

Note: PDF documents on this site were created using Adobe Acrobat 5.0 or later. Document functionality may be reduced if you are using an earlier version (4.x or less). Get the latest version of Adobe Acrobat.



Public Health has made reasonable efforts to provide accurate translation. However, no computerized translation is perfect and is not intended to replace traditional translation methods. If questions arise concerning the accuracy of the information, please refer to the English edition of the website, which is the official version.

Los Angeles County Seal: Enriching lives through effective and caring services